Verheugt FW - Search Results

1

Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention.

Verheugt FW, Steinhubl SR, Hamon M, Darius H, Steg PG, Valgimigli M, Marso SP, Rao SV, Gershlick AH, Lincoff AM, Mehran R, Stone GW. Verheugt FW, et al. JACC Cardiovasc Interv. 2011 Feb;4(2):191-7. doi: 10.1016/j.jcin.2010.10.011. JACC Cardiovasc Interv. 2011. PMID: 21349458 Free article.

2

Bleeding risk of combined oral anticoagulant and antiplatelet therapy in cardiovascular disease.

Verheugt FW. Verheugt FW. J Cardiovasc Risk. 1996 Apr;3(2):229-32. J Cardiovasc Risk. 1996. PMID: 8836868

3

Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study.

van den Merkhof LF, Zijlstra F, Olsson H, Grip L, Veen G, Bär FW, van den Brand MJ, Simoons ML, Verheugt FW. van den Merkhof LF, et al. Among authors: verheugt fw. J Am Coll Cardiol. 1999 May;33(6):1528-32. doi: 10.1016/s0735-1097(99)00038-8. J Am Coll Cardiol. 1999. PMID: 10334418 Free article.

4

Management strategies in unstable coronary artery disease--current problems and future directions. The UCAD Council.

Verheugt FW, Becker RC, Bertrand ME, Bode C, Chesebro JH, Cleland JG, Conti R, Hillis WS, Klein W, Maseri A, Turpie AG, Wallentin L, Waters DD. Verheugt FW, et al. Clin Cardiol. 1999 Sep;22(9):551-3. doi: 10.1002/clc.4960220903. Clin Cardiol. 1999. PMID: 10486693 Free PMC article.

5

Low-molecular-weight heparin and other antithrombotic agents in the setting of a primarily medical treatment of unstable coronary artery disease.

Verheugt FW. Verheugt FW. Haemostasis. 2000;30 Suppl 2:122-7; discussion 106-7. doi: 10.1159/000054177. Haemostasis. 2000. PMID: 11251355 Review.

6

GP IIB/IIIA blockers with and without thrombolytic agent in prehospital treatment of acute myocardial infarction.

Verheugt FW. Verheugt FW. Thromb Res. 2001 Sep 30;103 Suppl 1:S113-6. doi: 10.1016/s0049-3848(01)00307-3. Thromb Res. 2001. PMID: 11567678 Review.

7

Glycoprotein IIb/IIIa blockers in non-ST elevation acute coronary syndromes: only for well defined subgroups or a therapeutic option for all patients?

Verheugt FW. Verheugt FW. J Thromb Thrombolysis. 2003 Apr;15(2):81-4. doi: 10.1023/b:thro.0000003309.34726.b4. J Thromb Thrombolysis. 2003. PMID: 14618073 Review.

8

Low-dose aspirin for primary prevention of cardiovascular disease.

Bredie SJ, Wollersheim H, Verheugt FW, Thien T. Bredie SJ, et al. Among authors: verheugt fw. Semin Vasc Med. 2003 May;3(2):177-84. doi: 10.1055/s-2003-40675. Semin Vasc Med. 2003. PMID: 15199480

9

[Antithrombotic therapy during percutaneous coronary interventions].

Verheugt FW, Dieker H, Aengevaeren WR. Verheugt FW, et al. Ned Tijdschr Geneeskd. 2005 Apr 23;149(17):912-6. Ned Tijdschr Geneeskd. 2005. PMID: 15884403 Review. Dutch.

10

New anticoagulants in ischemic heart disease.

Verheugt FW. Verheugt FW. Presse Med. 2005 Oct 22;34(18):1325-9. doi: 10.1016/s0755-4982(05)84181-8. Presse Med. 2005. PMID: 16269997 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

619 results

Search Page